Royalty Pharma (RPRX) provided an update on its business performance, including recent key accomplishments. Key highlights include: Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties; Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion; Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including data readouts for daraxonrasib, litifilimab and pelacarsen
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
- Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
- Royalty Pharma Announces Planned Legal Leadership Transition
- Royalty Pharma Gains From FDA Approval of MYQORZO